Rejection of the component tissues of limb allografts in rats immunosuppressed with FK-506 and cyclosporine.
One-hundred and fourteen limb transplantations have been performed across a major histoincompatibility barrier between donor ACI (RT1a) and recipient Lewis (RT1l) rats immunosuppressed with various dosages of FK-506 and cyclosporine. Three-hundred and thirty biopsy specimens from 64 animals have been evaluated histologically for signs of rejection. A new histologic grading system is introduced to classify the process of rejection in the component tissues (skin, muscle, bone, and articular cartilage) of a limb allograft. The results indicate that FK-506 is a more potent immunosuppressive agent than cyclosporine in preventing the rejection of the skin component of a limb transplant. With twice-weekly intermittent immunosuppression with FK-506, the rejection of muscle, bone, and cartilage can be prevented for an indefinite time, although all long-term surviving animals died at around 300 days, probably of graft-versus-host disease. Based on the histologic stages of rejection in the different tissues at the same point in time, it is evident that each component tissue of a limb transplant rejects over a different time period. This probably reflects a hierarchy of antigenicity, with skin being most antigenic, muscle being intermediate in antigenicity, and bone and cartilage being least antigenic. Although this grading system is not the ultimate solution, it may allow a more objective comparison of experimental limb transplantation in the future.
Büttemeyer
R
R
Division of Plastic and Reconstructive Surgery, University of California, Los Angeles, USA.
Jones
N F
NF
Min
Z
Z
Rao
U
U
D000704:Analysis of Variance; D000818:Animals; D001706:Biopsy; D001842:Bone and Bones / Q000473:pathology; D002358:Cartilage, Articular / Q000473:pathology; D016572:Cyclosporine / Q000008:administration & dosage*; D004334:Drug Administration Schedule; D004817:Epidermis / Q000473:pathology; D005355:Fibrosis; D006084:Graft Rejection / Q000473:pathology / Q000517:prevention & control*; D006614:Hindlimb / Q000637:transplantation*; D007165:Immunosuppression Therapy / Q000009:adverse effects; D018482:Muscle, Skeletal / Q000473:pathology; D009336:Necrosis; D018410:Pneumonia, Bacterial / Q000209:etiology; D051381:Rats; D011912:Rats, Inbred ACI; D011917:Rats, Inbred Lew; D016559:Tacrolimus / Q000008:administration & dosage*
D016572:Cyclosporine; D016559:Tacrolimus